Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma

Glioblastoma Multiforme (GBM) is still an incurable disease. The front-line Temozolomide (TMZ)-based therapy suffers from poor efficacy, underlining the need of new therapies. Preclinically, Aldoxorubicin (Aldox), a novel prodrug of Doxorubicin (Dox), has been successfully tested against GBM, encour...

Descripción completa

Detalles Bibliográficos
Autores principales: Da Ros, Martina, Iorio, Anna Lisa, De Gregorio, Veronica, Fantappiè, Ornella, Laffi, Giacomo, de Martino, Maurizio, Pisano, Claudio, Genitori, Lorenzo, Sardi, Iacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201851/
https://www.ncbi.nlm.nih.gov/pubmed/30405885
http://dx.doi.org/10.18632/oncotarget.26183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201851/
https://www.ncbi.nlm.nih.gov/pubmed/30405885
http://dx.doi.org/10.18632/oncotarget.26183

Ejemplares similares